Arcutis Must Prove Zoryve Volume Can Carry Growth As Pricing Tailwind Fades

Arcutis Biotherapeutics enters its third-quarter report with something it has rarely had: a raised outlook and a profitable quarter behind it. The harder question is whether Zoryve's second-quarter surge was the start of a sustained climb or a burst helped along by pricing. Management has already said the gross-to-net improvement that flattered recent results will level off in the back half of the year. That makes this the first report where prescription volume has to do nearly all the work.

Wall Street expects earnings of $0.17 per share on revenue of $141.6 million when the company reports after the close on November 4. That would be roughly 43% revenue growth from the $99.2 million posted a year ago and close to a tripling of the year-ago $0.06 in EPS. Growth is still strong, but it is slower than the 59% year-over-year gain in the second quarter. Sequentially, the estimate implies about a 9% step up from $129.9 million, a far gentler climb than the 23% jump the company delivered last quarter.

The guidance math makes the setup more interesting. Arcutis raised its 2026 net product sales forecast to $525 million to $540 million, up from the $480 million to $495 million range it had set at the start of the year and pointedly left unchanged in the first quarter. With about $235 million booked in the first half, the company needs roughly $290 million to $305 million over the final two quarters, or about $145 million to $152 million per quarter. The third-quarter consensus sits a little below that pace. The full-year consensus of about $502 million sits below the low end of the range, which suggests some estimates have not caught up with the raise or reflect skepticism about it. A print in the mid-$140 millions would go a long way toward showing the new range is realistic rather than aspirational.

The operating evidence matters more than the headline beat. Quarterly prescriptions topped 280,000 last quarter, a record, and that number needs to keep rising now that net pricing is settling in the low 50s. The expanded dermatology sales force has been in the field since early May, so this is the first full quarter that can show whether the added reps are lifting prescriptions. The late-June approval of Zoryve cream 0.3% down to age 2 in psoriasis should also start showing up. Commentary on the telehealth platform and the AI-enabled prescription workflow partnership will be early, and the economics of the virtual channel remain unproven. The new primary care and pediatric team only reached the field by late August, and management has said not to expect a real contribution until 2027.

There is also a people question. Chief commercial officer Todd Edwards left with an interim leader stepping in during a national search. Any hint that execution slipped during the handoff would land poorly given how many commercial initiatives are ramping at once. Updates on the vitiligo Phase 2 program and the infant atopic dermatitis filing, which has a February 23, 2027 decision date, round out the pipeline picture.

The stock has gained about 9% since the last report while the S&P 500 slipped, and it trades well above its 200-day moving average near $25. At $31.81 it sits in the upper part of its post-earnings range, though still a few percent shy of the $33.30 high. Sentiment, meanwhile, has turned more bearish than it was heading into last quarter. That pairing of a rising stock and growing skepticism suggests investors expect the raised guidance to be tested. In the end, the report hinges on one thing: whether prescription growth is strong enough to keep revenue on a $145 million-plus quarterly path without help from pricing. If it is, the raise looks conservative. If it is not, the first half may prove to have been the easy part.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.